NBIX – Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc.NBIX
$126.32Name : Neurocrine Biosciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $12,677,912,576.00
EPSttm : 4.67
Neurocrine Biosciences, Inc.
$126.32
1.99%$2.57
NBIX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
4.67
Margin Of Safety %
20
Put/Call OI Ratio
1.54
EPS Next Q Diff
-1.41
EPS Last/This Y
2.86
EPS This/Next Y
0.88
Price
126.31
Target Price
182.19
Analyst Recom
1.37
Performance Q
-6.97
Upside
29.4%
Beta
0.36
Ticker: NBIX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | NBIX | 130.23 | 1.46 | 0.17 | 8923 |
| 2026-03-18 | NBIX | 130.71 | 1.46 | 2.00 | 8927 |
| 2026-03-19 | NBIX | 129.19 | 1.46 | 0.14 | 8925 |
| 2026-03-20 | NBIX | 127.69 | 1.45 | 0.87 | 8926 |
| 2026-03-23 | NBIX | 127.04 | 1.57 | 0.27 | 8610 |
| 2026-03-24 | NBIX | 127.84 | 1.57 | 0.12 | 8617 |
| 2026-03-25 | NBIX | 131.1 | 1.57 | 0.17 | 8637 |
| 2026-03-26 | NBIX | 132.41 | 1.56 | 0.09 | 8641 |
| 2026-03-27 | NBIX | 128.3 | 1.56 | 0.29 | 8649 |
| 2026-03-30 | NBIX | 128.67 | 1.56 | 0.97 | 8652 |
| 2026-03-31 | NBIX | 131.71 | 1.52 | 0.25 | 9248 |
| 2026-04-01 | NBIX | 132.6 | 1.52 | 0.06 | 9257 |
| 2026-04-02 | NBIX | 131.56 | 1.51 | 0.00 | 9263 |
| 2026-04-06 | NBIX | 132.47 | 1.51 | 5.76 | 9263 |
| 2026-04-08 | NBIX | 133.15 | 1.56 | 0.53 | 9439 |
| 2026-04-09 | NBIX | 131.7 | 1.55 | 0.41 | 9416 |
| 2026-04-13 | NBIX | 126.26 | 1.54 | 0.21 | 9453 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | NBIX | 130.70 | 146.3 | 194.1 | 7.96 |
| 2026-03-18 | NBIX | 130.66 | 146.3 | 187.9 | 7.96 |
| 2026-03-19 | NBIX | 129.63 | 146.3 | -12.0 | 7.96 |
| 2026-03-20 | NBIX | 127.68 | 146.3 | -17.0 | 7.96 |
| 2026-03-23 | NBIX | 127.15 | 146.3 | -9.2 | 7.96 |
| 2026-03-24 | NBIX | 127.81 | 146.3 | -2.1 | 7.96 |
| 2026-03-25 | NBIX | 131.05 | 146.3 | 10.8 | 7.96 |
| 2026-03-26 | NBIX | 132.49 | 146.3 | 0.7 | 7.96 |
| 2026-03-27 | NBIX | 128.31 | 146.3 | -27.9 | 7.96 |
| 2026-03-30 | NBIX | 128.66 | 146.3 | -4.4 | 7.96 |
| 2026-03-31 | NBIX | 131.71 | 146.3 | 9.7 | 7.96 |
| 2026-04-01 | NBIX | 132.55 | 146.3 | -2.0 | 7.96 |
| 2026-04-02 | NBIX | 131.59 | 146.3 | -11.4 | 7.96 |
| 2026-04-06 | NBIX | 132.52 | 146.3 | -1.5 | 7.96 |
| 2026-04-07 | NBIX | 130.91 | 146.3 | -14.7 | 7.96 |
| 2026-04-09 | NBIX | 131.64 | 146.3 | 159.4 | 7.96 |
| 2026-04-10 | NBIX | 128.91 | 147.5 | 151.3 | 7.67 |
| 2026-04-13 | NBIX | 126.31 | 147.5 | 151.8 | 7.67 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | NBIX | -3.56 | 1.72 | 3.46 |
| 2026-03-18 | NBIX | -3.56 | 1.72 | 3.46 |
| 2026-03-19 | NBIX | -3.56 | 1.72 | 3.46 |
| 2026-03-20 | NBIX | -3.56 | 1.72 | 3.46 |
| 2026-03-23 | NBIX | -3.56 | 1.83 | 3.46 |
| 2026-03-24 | NBIX | -3.56 | 1.83 | 3.46 |
| 2026-03-25 | NBIX | -3.56 | 1.83 | 3.95 |
| 2026-03-26 | NBIX | -3.56 | 1.83 | 3.95 |
| 2026-03-27 | NBIX | -3.56 | 1.83 | 3.95 |
| 2026-03-30 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-03-31 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-01 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-02 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-06 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-07 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-08 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-09 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-10 | NBIX | -3.56 | 1.81 | 3.95 |
| 2026-04-13 | NBIX | -3.56 | 1.85 | 4.67 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.33
Avg. EPS Est. Current Quarter
1.72
Avg. EPS Est. Next Quarter
1.92
Insider Transactions
-3.56
Institutional Transactions
1.85
Beta
0.36
Average Sales Estimate Current Quarter
771
Average Sales Estimate Next Quarter
844
Fair Value
151.24
Quality Score
80
Growth Score
99
Sentiment Score
49
Actual DrawDown %
21.2
Max Drawdown 5-Year %
-42.9
Target Price
182.19
P/E
27.06
Forward P/E
15.08
PEG
0.47
P/S
4.43
P/B
3.89
P/Free Cash Flow
16.93
EPS
4.67
Average EPS Est. Cur. Y
7.67
EPS Next Y. (Est.)
8.55
Target Price Estimates Raised
2
Target Price Estimates Lowered
2
Profit Margin
16.73
Relative Volume
0.97
Return on Equity vs Sector %
-12.6
Return on Equity vs Industry %
7.3
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.28
EBIT Estimation
151.8
◆
NBIX
Healthcare
$126.32
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40.5
Range 1M
14.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
31.3%
EPS NY
36.7%
52W%
50.3%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+83.2% upside
Upside
+83.2%
Quality
80
MoS
20%
Neurocrine Biosciences, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2000
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
NBIX
Latest News
—
Caricamento notizie per NBIX…
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading